Scientists Successfully Slow Down Light by 10,000 Times!

An illustration depicts gravitational waves stretching and squeezing space-time in the universe, June, 2023. (AP Photo)
An illustration depicts gravitational waves stretching and squeezing space-time in the universe, June, 2023. (AP Photo)
TT

Scientists Successfully Slow Down Light by 10,000 Times!

An illustration depicts gravitational waves stretching and squeezing space-time in the universe, June, 2023. (AP Photo)
An illustration depicts gravitational waves stretching and squeezing space-time in the universe, June, 2023. (AP Photo)

A new study demonstrates a method for slowing down light that promises to be one of the most useful approaches yet.

The researchers behind the breakthrough, from Guangxi University and the Chinese Academy of Sciences in China, say that their method could benefit computing and optical communication.

Light zipping through the emptiness of space moves at one speed and one speed only - 299,792 kilometers (about 186,000 miles) per second. Yet if you throw a mess of electromagnetic fields into its path, such as those surrounding ordinary matter, that extraordinary velocity starts to slow.

Most transparent materials will slow light by a tiny fraction. It's the changes in speed that cause light to bend as it passes from one medium to another.

But really putting the brakes on requires special materials like photonic crystals or even super-chilled quantum gases.

"We envision that our work provides an entirely new direction for realizing ultra-strong light-matter interactions in nanophotonic chips," write the researchers in their published paper.

The new method builds on what's known as electromagnetically induced transparency (EIT), which uses a clever bit of laser trickery to manipulate electrons inside gas that's stored in a vacuum – essentially turning it from opaque to transparent, reported the Science Alert website. This means laser light can pass through, but because of how it has been manipulated, it also slows down. That makes it very interesting for physicists, but the approach also means a lot of the light and energy is lost along the way.

To reduce this loss and improve the whole system's efficiency, the researchers took some of the principles of EIT in controlling light and designed a new material to slow down light.

The material is a kind of metasurface (a synthetic, 2D structure with properties unlike any in nature).

The metasurfaces designed by the team were made from very thin layers of silicon – like today's computing chips – and were shown to be much better than existing options.

Based on the results obtained by the researchers, light can be slowed down by more than 10,000 times in this system.

At the same time, the light loss is reduced by more than five times compared with other comparable methods. Key to the new approach is the way that the tiniest building blocks of the metasurface (known as meta-atoms) are positioned. In this case, they're essentially close enough to merge together, which in turn affects the way that light is handled as it passes through.

The end result is all of this complex science is better control over how light travels.

As light plays such a key role in everything from broadband internet to quantum computing, there's a multitude of potential applications.

It's not the only way that scientists have found to further slowdown light, beyond the natural slowing that happens in substances like water, but its effectiveness and its scalability make it a promising option for further study.

"With these findings, our study opens a new route for tailoring light flow in metasurfaces," write the researchers.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”